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Objectives: Ankylosing spondylitis (AS) is a multifactorial and polygenic disease. Apart from HLA, other
genes very probably play a role in disease susceptibility. Indigenous bacteria of the gastrointestinal flora
appear to play a role in the pathogenesis of the disease; therefore, genes controling the innate and
acquired immune response are good candidates to study disease susceptibility. CD14 and Toll-like
receptor 4 (TLR4) are key receptors for the sensing of bacteria. The CD14 C-260T and TLR4 A896G single
nucleotide polymorphims are associated with aberrant signal transduction for bacterial agonists.
Methods: The distribution of the CD14 C-260T and TLR4 A896G polymorphisms was studied in genomic
DNA from 113 unrelated white Dutch AS patients and 170 ethnically matched healthy controls. The
diagnosis of AS was made according to the modified New York criteria. The CD14 C-260T and TLR4
A896G polymorphisms were genotyped by PCR-RFLP methods.
Results: No significant differences were found between patients and controls in the frequencies of the
carriership of the less frequent CD14-260T allele (odds ratio 0.65; 95% confidence interval 0.37 to 1.15)
or the TLR4 896G allele (1.68; 0.67 to 4.19).
Conclusions: There is no evidence for involvement of the CD14 C-260T or TLR4 A896G polymorphisms in
susceptibility to AS. An important role of bacteria and genetic predisposition of the innate immune system
in cases of AS cannot be excluded by these findings. Therefore, studies of the surprisingly highly
polymorphic candidate genes in this field should be continued.
D
espite the discovery of the association between anky-
losing spondylitis (AS) and HLA-B27 over thirty years
ago,1 2 the precise role of the adaptive and innate
immune system in the pathogenesis of this common
rheumatic disorder has not been clarified.
Apart from genetic factors, bacteria are thought to be
crucial in the pathogenesis of AS, the prototype of the
spondylarthropathies. Over the past decades it has been
shown that bacterial infections can trigger the onset of at
least one type of spondylarthropathy, reactive arthritis (ReA).
ReA occurs frequently after infectious diarrhoea caused by
Shigella flexneri, Salmonella typhimurium and enteritides, Yersinia
enterocolitica, or Campylobacter jejuni,3 or can be caused by
urogenital infections with Chlamydia trachomatis (for a review,
see Zeidler and Schumacher4). However, so far no specific
pathogen has been consistently linked to the development of
AS.5
The acquired and the innate immune systems play
important roles in the host defence against pathogens.
Innate immunity refers to the inborn resistance that is
already present the first time a pathogen is encountered; it
does not require prior exposure and is not modified
significantly by repeated exposures to the pathogen over
the life of an individual. Acquired immunity refers to
resistance that is weak or absent on first exposure, but that
increases dramatically with subsequent exposures to the
same specific pathogen.
Cluster of differentiation 14 (CD14) and Toll-like receptor 4
(TLR4) are, together with the MD-2 protein, part of the
lipopolysaccharide (LPS) receptor complex of the innate
immune system. LPS is a glycolipid specific to gram negative
bacterial cell walls. CD14 is the receptor of monocytes/
macrophages for complexes of LPS and LPS binding protein
(LBP).6 LPS is transferred from a CD14/LBP complex to a
TLR4/MD-2 membrane receptor complex at the cell surface.7
A transmembrane signal leads to nuclear factor (NF)-kB
activation, subsequent induction of gene transcription and
release of pro-inflammatory cytokines, such as tumour
necrosis factor a, initiating inflammation.8
Besides LPS, other bacterial and host agonists are reported
to be recognised by TLR4 including C. trachomatis and host
heat shock protein 60 (HSP60) ligands.9
Although, to the best of our knowledge there is no evidence
for linkage in the region of the CD14-260 single nucleotide
polymorphism (SNP) on chromosome 5q31, functional
studies imply this gene may be of relevance to AS. The
CD14-260 promoter SNP enhances transcriptional activity,10
and is associated with enhanced monocyte CD14 expres-
sion.11 12 Individuals carrying the TT genotype have signifi-
cantly higher serum levels of soluble CD14 than have those
with CC or CT genotypes and they have increased density of
CD14 in blood monocytes.11 12
Recently, allele CD14-260T has been found to be signifi-
cantly positively associated with ulcerative colitis (UC) in
Japan.13 However, in Germany, the allele CD14-260T and the
genotype TT were increased in Crohn’s disease (CD) but not
in UC.14 More recently, the same group of investigators found
allele CD14-260T and TT genotype frequencies of the CD14
SNP to be significantly increased only in patients with CD
carrying at least one of the susceptibility variants Arg702Trp,
Abbreviations: AS, ankylosing spondylitis; CD, Crohn’s disease; HSP,
heat shock protein; LBP, lipopolysaccharide binding protein; LPS,
lipopolysaccharide; NF, nuclear factor; SNP, single nucleotide
polymorphism; TLR, Toll-like receptor; UC, ulcerative colitis
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Gly908Arg, or Leu1007fsinsC in the CARD15 gene.15 Both UC
and CD can have disease manifestations that belong to the
spondylarthropathies.
So far, there have been no studies addressing the possible
association of the CD14-C260T SNP with AS, although
carriage of the CD14-260T allele might increase the suscept-
ibility of female patients to the development of chronic
spondylarthropathy.16
The TLR4 gene is located on chromosome 9q32-q33 at
115.8 Mb. Genome scanning in AS identified linkage to a
region on chromosome 9q. Marker D9S1826 on chromosome
9q34 at 133.9 Mb achieved a lod score of 2.8 (p,0.0005), and
marker D9S1682 at 120.4 Mb achieved a lod score of 2.3
(p,0.005), both suggestive of linkage.17 Given the distance
between the TLR4 gene and the D9S1826 and D9S1682
markers, it is unlikely that TLR4 can warrant the linkage to
the region on chromosome 9. Nevertheless, similar to the
situation in CD14, functional studies imply that TLR4 might
be of relevance to AS.
The A896G SNP is located in the ectoplasmic receptor
domain of TLR4, resulting in an aspartic acid to glycine
substitution at position 299. Recently, the A896G SNP was
shown to be associated with ‘‘an endotoxin hyporesponsive
phenotype’’ in concert with other genetic changes or acquired
factors that influence the complex physiological response to
LPS.18 However, monocytes from individuals heterozygous for
allele TLR4 896G do not exhibit a deficit in recognition of LPS
from several bacterial strains.19 Moreover, the heterozygous
TLR4 A896G polymorphism does not influence LPS induced
human whole blood cytokine release20. Other agonists for
TLR4 have not yet been tested functionally.
The present study was designed to study the frequency of
the CD14 C-260T and TLR4 A896G SNPs in AS to find out
whether these polymorphisms contribute to disease suscept-
ibility and clinical manifestations.
PATIENTS AND METHODS
Subjects
After informed consent, 113 AS patients were recruited from
the outpatient Department of Rheumatology of the Jan van
Breemen Institute. All AS patients fulfilled the diagnosis of
AS, according to the modified New York criteria.21 Controls
were 170 randomly selected healthy blood donors from the
Amsterdam region. All subjects were unrelated Dutch whites.
Methods
Genotyping the CD14 C-260T SNP (NCBI SNP cluster ID:
rs2569190) was performed with forward primer 59-TCACC
TCCCCACCTCTCTT-39 and 59-CCTGCAGAAT-CCTTCCTGTT-
39. Digestion overnight with HaeIII (New England Biolabs,
UK) of the 107 bp amplicons was followed by separation by
electrophoresis on 4% agarose gels, staining with ethidium
bromide, and visualisation under ultraviolet light, and
resulted in two fragments of 83 and 24 bp (C allele) or
107 bp (T allele).
Genotyping of the TLR4 A896G SNP (NCBI SNP cluster ID:
rs4986790) was performed as described by Morre´ et al.22
Statistical analysis
Allele and genotype frequencies were tested for Hardy-
Weinberg equilibrium by x2 test. To compare frequencies,
x2 or Fisher’s exact test was used. The possible influence of
interaction of the two studied polymorphisms in patients and
controls was analysed by logistic regression. A two sided p
value ,0.05 was considered significant. The magnitude of
association was expressed as odds ratio with a 95%
confidence interval (CI). Statistical analysis was performed
by SPSS 10.0 for Windows.
RESULTS
Characteristics of the 113 AS patients are summarised in
table 1. Genotype and allele frequencies in AS patients and
controls for the CD14 C-260T and the TLR4 A896G SNP in
table 2. The genotype frequencies in the control group did not
deviate from HWE equilibrium. No significant differences
were observed between AS patients and controls in the
frequencies of carriership of the CD14-260T and TLR4 896G
alleles (table 2). Logistic regression analysis showed absence
of modification of the odds ratios (OR). Thus, no interaction
between the CD14 C-260T and TLR4 A896G polymorphisms
was found (data not shown).
No significant associations were found between carriage of
each of the alleles CD14-260T and TLR4 896G with sex,
existence in past or present of peripheral arthritis or acute
anterior uveitis, age at first complaints, years between first
complaints and actual diagnosis of AS, or the number of
patients with at least one first degree family member with AS
(table 3).
DISCUSSION
The studied SNPs reported to affect gene function in two
genes that play a role in innate immunity, CD14 C-260T and
TLR4 A896G, are not significantly associated with the
susceptibility to or the clinical manifestations of AS.
Table 1 Demographic and clinical
characteristics of patients with ankylosing
spondylitis (n = 113)
Characteristics
Age, years* 52.6 (12.5; 19 to 79)
Age at first complaints, years 23.0 (19.0 to 31.5)
Age at actual diagnosis, years 34.0 (25.0 to 42.5)
Years between first complaints
and diagnosis
7.0 (2.0 to 12.5)
Women 12.5%
HLA-B27 positive 98%
Iridocyclitis 40%
Peripheral arthritis 37%
First degree relatives with AS 28%
*Mean (SD; range), median (interquartile range).
Table 2 Allele and genotype frequencies of the CD14 C-
260T and the TLR4 A896G polymorphisms in ankylosing
spondylitis patients and controls
AS patients
(n = 113)
Controls
(n = 170) p
CD14 C-260T
Allele
C 111 (49.1%) 178 (52.4%) OR = 0.88
95% CI =
0.63 to 1.23
0.45
T 115 (50.9%) 162 (47.6%)
Genotype
CC 23 (20.4%) 48 (28.2%) x2 = 2.87 0.24
CT 65 (57.5%) 82 (48.2%)
TT 25 (22.1%) 40 (23.5%)
TLR4 A896G
Allele
A 219 (96.9%) 322 (94.7%) OR = 1.75
95% CI =
0.72 to 4.26
0.21
G 7 (3.1%) 18 (5.3%)
Genotype
AA 106 (93.8%) 153 (90.0%) x2 = 1.64 0.44
AG 7 (6.2%) 16 (9.4%)
GG 0 (0%) 1 (0.6%)
No significant difference was found between patients and controls in the
frequencies of the carriership of the CD14-260T (OR 0.65; 95% CI 0.37
to 1.15) or TLR4 896G (OR 1.68; 95% CI 0.67 to 4.19) allele.
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Nevertheless, this study cannot exclude that specific pheno-
typic features of AS are related to TLR4 and/or CD14
genotypes. Therefore, it would be of interest to assess
whether the CD14 C-260T and TLR4 A896G SNPs are
associated with disease severity (C-reactive protein, ESR,
Bath Ankylosing Spondylitis Disease Activity Index, Bath
Ankylosing Spondylitis Functional Index), anatomical evolu-
tion (Bath Ankylosing Spondylitis Metrology Index, sacro-
iliitis, degree of ankylosis), or involvement of the gut.
Moreover, although this study could not find a significant
association between CD14 C-260T and TLR4 A896G and the
clinical manifestations of AS, the number of patients in this
analysis was too low to warrant a definitive conclusion.
Bacteria are thought to play a crucial role in the
pathogenesis of AS. In animal models such as B27 transgenic
rats, in ,50% of the cases, the presence of the bacterial flora
is obligatory for development of inflammatory gut lesions
and peripheral and axial inflammatory joint lesions, similar
to AS. When raised in a germfree environment, inflammatory
intestinal or joint disease does not develop until the normal
bacterial flora is restored.23
AS occurs frequently in patients with newly diagnosed
inflammatory bowel disease—that is, UC or CD.24 On the
other hand, patients with spondylarthropathies often have
subclinical gut involvement.25 This gut inflammation is
clinically and histologically closely related to CD.26 27
It is likely that an altered host response of the innate
immune system may contribute to the development of AS.
This hypothesis is supported by the findings on genetic
susceptibility of CD, which have shifted the focus of research
in this disease towards innate immunity. The relationship
with acquired immunity provides a good insight into the
mechanisms that control inflammation in the gut.28 Recently,
IgA levels of anti-Saccharomyces cerevisiae mannan antibodies,
a marker of CD, have been found to be significantly higher in
patients with spondylarthropathies, and more specifically in
AS, than in healthy controls and patients with rheumatoid
arthritis.29
Besides the association reported with CD14,15 an estab-
lished genetic association of the innate immune system with
CD is the Leu1007fsinsC insertion mutation at position 3020
in the CARD15 gene, located on chromosome 16p12. This
mutation was described as an important susceptibility factor
for CD.30–33 However, studies from our group in the
Netherlands,34 and from Spain35 and the UK36 have disproved
that the commonest CARD15 mutations found in these
populations contribute to the disease susceptibility in primary
AS.
The identification and functional characterisation of
mutants, such as those in CD14, TLR, and NOD2/CARD15
receptors, provide a new insight into the relationships
between bacteria and the host, and between bacteria and
the development of disease.37 38 A previous study in Germany
in a population of similar ethnic background to the one we
have studied has revealed interactions of the CARD15 and
CD14 genes that increase the risk for developing CD.15
Interestingly, so far the associations found in the three genes
CD14, CARD15, and TLR4 have not been reproduced in all
population studies demonstrating the complexity of the
interaction between genes and environment. As recently
described by Vercelli,39 ‘‘Genetic variation in innate immunity
genes at the interface with the environment may skew the
human immune response in critical ways by modulating the
impact of pathogen exposure’’. Therefore, although we found
no significant associations between the CD14-C260T and
TLR4 A896G SNPs with AS in general or with clinical
characteristics, the significance of functional polymorphisms
in genes that are involved in innate immunity deserve to be
studied in this disease, in which bacteria and HLA appear to
be important in the pathogenesis.
These are early days in the studies of innate immunity in
AS and in many other chronic inflammatory diseases. It is
possible that polymorphisms in other receptors sensing other
bacteria than the ones recognised by CD14, TLR4, and CARD15
may prove to be important in understanding the synergy
between clinical manifestations, epidemiology, molecular
biology, and pathophysiology of inflammation.
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Table 3 Clinical characteristics of patients with ankylosing spondylitis (n = 113) in relation to carriage of the CD14-260T or the
TLR4 896G allele
Characteristics
TLR4 896G CD14 260T
Carrier Non-carrier OR (95% CI) p Carrier
Non-
carrier OR (95% CI) p
Female/male 1/6 12/85 1.18
(0.13 to 10.67)
1.0 11/72 2/19 1.45
(0.30 to 7.11)
1.0
PA (+/2) 3/4 35/60 0.78
(0.16 to 3.68)
1.0 33/48 5/16 0.46
(0.15 to 1.36)
0.15
AAU(+/2) 5/2 34/57 0.24
(0.04 to 1.30)
0.11 31/48 8/11 1.13
(0.41 to 3.11)
0.82
Familial(+/2) 2/4 23/61 0.75
(0.13 to 4.40)
0.67 21/51 4/14 0.69
(0.20 to 2.36)
0.56
Age at first
complaints, mean
(SD) (range)
23.83 (6.18)
(18 to 32)
25.64 (9.78)
(9 to 55)
0.57* 25.17 (9.39)
(9 to 51)
25.89 (10.37)
(16 to 55)
0.63*
Years to actual
diagnosis, mean
(SD) (range)
9.08 (11.43)
(1 to 32)
9.27 (8.83)
(1 to 40)
0.77* 8.99 (8.79)
(1 to 37)
10.33 (9.74)
(1 to 40)
0.43*
AAU, acute anterior uveitis; PA, peripheral arthritis; familial, patients with at least one first degree family member with AS; +/2, present/not present; years to
actual diagnosis, number of years between the first complaints and the actual diagnosis of AS. *Mann-Whitney test.
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